Madrigal Pharmaceuticals Inc. Company Profile
NASDAQ: MDGLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Madrigal Pharmaceuticals at a glance
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in West Conshohocken, PA. Madrigal Pharmaceuticals is led by Mr. William J. Sibold and employs about 915 people. The company's shares have traded publicly since 2007.
At a market capitalization of $11.47 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0001157601, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Madrigal Pharmaceuticals do?
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Business description based on the company's public filings.
Company information
- Legal name
- Madrigal Pharmaceuticals Inc.
- Ticker
- NASDAQ: MDGL
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. William J. Sibold
- Employees
- 915
- Headquarters
- 1001 Conshohocken State Road, West Conshohocken, PA, United States
- Phone
- 267 824 2827
- Website
- madrigalpharma.com
- IPO year
- 2007
- Market cap
- $11.47B
- SEC CIK
- 0001157601
Companies similar to Madrigal Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ELANElanco Animal Health Incorporated | 22.36 | -0.53% | $11.17B | vs MDGL |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs MDGL |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs MDGL |
| CORTCorcept Therapeutics Incorporated | 119.60 | +0.03% | $12.93B | vs MDGL |
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs MDGL |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs MDGL |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs MDGL |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs MDGL |